Find Clinical Trials

Inclusion Criteria: * Spanish speakers * OASIS score +/= 8 * ODSIS score +/= 7 * Access to Internet * Email Exclusion Criteria: * Severe mental disorder: schizophrenia/bipolar disorder * Active substance abuse * High suicide risk * Ongoing psychological/pharmacological treatment * Interfering physical illness

Inclusion Criteria: 1. Must be at least 18 years of age. 2. Patients must have completed initial diagnosis visit with oncologist or surgeon. 3. Must have pathology slides and reports available for review. 4. Must be able to speak English. 5. Must be willing to participate in this research and will be provided with an information sheet. 6. Pregnant women are eligible as this research poses no risk of physical harm to the participant. Exclusion Criteria: 1. Patients \<18 years of age. 2. Patients with DCIS are ineligible. 3. Adults who are unable to provide written signature. 4. Patients from vulnerable patient populations, including infants, minors, those unable to provide informed consent, and those incarcerated or imprisoned at the time of enrollment.

Inclusion Criteria: * Females aged ≥18 years * HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension * BMI ≥25 kg/m2 prior to pregnancy or in the first trimester * Requirement for antihypertensive medication within one week of delivery * Ability to provide informed consent Exclusion Criteria: * LV ejection fraction \<50% or history of clinical heart failure with reduced or preserved ejection fraction * Hypertrophic or other genetic cardiomyopathy * Hyperkalemia: potassium \>5.3 mEq/L * BMI at screening ≥50 kg/m2 * Pre-pregnancy diabetes * Estimated glomerular filtration rate (eGFR) \<60mL/min/1.73 m2 * Cirrhosis * Primary aldosteronism * Intention to become pregnant within 9 months * Active substance abuse * Other serious medical illnesses or concerns about protocol adherence/ mortality within 9 months * Participation in another interventional clinical study * Hypersensitivity to spironolactone * Addison's disease * Concomitant use of eplerenone or finerenone

Inclusion Criteria: * Women aged between 18 and 75 years with a prior diagnosis of stage 0-III breast cancer. * Women currently in the survivorship phase of the disease, regardless of the type of medical or surgical treatment received. * A minimum of six months must have elapsed since the completion of primary treatment. Exclusion Criteria: * History of lymphedema secondary to axillary surgery. * Inability to provide informed consent for participation in the study. * Prior diagnosis of hearing impairments that hinder or prevent music listening, such as partial or total deafness. * Prior diagnosis of any central or peripheral neurological condition. * Presence of comorbidities or conditions that contraindicate participation in a physical exercise program. * A preliminary screening of participants will be conducted based on the recommendations of the National Comprehensive Cancer Network (NCCN), considering the risk of potential exercise-induced adverse effects.

Inclusion Criteria: 1. Female patients aged 18-70 years; 2. Histopathologically confirmed HER2 positive breast cancer; 3. Patients were diagnosed with stage II-III breast cancer; 4. At least one measurable target lesion according to RECIST V1.1; 5. ECOG performance status score of 0 to 1; 6. Life expectancy ≥12 weeks; 7. Adequate bone marrow reserve and organ system function reserve; 8. Participants should be able and willing to comply with the study protocol requirement; Exclusion Criteria: 1. Breast cancer not histologically confirmed; 2. Known inherited or acquired bleeding and thrombotic tendencies; 3. Known allergy or contraindication to the study drug and its excipients; 4. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.); 5. Concurrent receipt of any other form of anti-cancer therapy; 6. History of a second primary malignancy, except for adequately treated skin cancer; 7. Participation in other drug clinical trials within 4 weeks before enrollment; 8. Major surgical procedures unrelated to breast cancer within 4 weeks prior to the first drug administration, or not fully recovered from such procedures; 9. Presence of any active autoimmune disease or history of autoimmune disease with potential for recurrence; 10. Uncontrolled or significant cardiovascular and cerebrovascular diseases; 11. Subjects with known or suspected interstitial pneumonia; 12. Presence of active hepatitis B, hepatitis C, liver cirrhosis; 13. Pregnant or lactating female patients; 14. History of definite neurological or mental disorders, or any other conditions that the investigator believes make the patient unsuitable for participating in this study.

Inclusion Criteria: * women in pre-hospitalization with already established invasive breast cancer (T1-2) * over the age of 30 * with BI-RADS mammography pattern\> 1 * Written and signed informed consent for research * Negative history of adverse events to the use of iodinated and chelated contrast media of gadolinium * No significant renal impairment (EGFR\> 30 mL / min within three months before administration of the iodinated contrast medium) Exclusion Criteria: * women with breast implants * women under the age of 30 * Any contraindication to performing the MRI exam * Women with known BRCA 1 and BRCA 2 mutation

Inclusion Criteria: 1. Age 18-65 years; 2. Triple negative invasive breast cancer, with immunohistochemistry confirming that the primary lesion was ER- or ER\<10% and weakly expressed, PR-, HER 2-; 3. Patients who had surgery after neoadjuvant immunotherapy, and required a hypofractionated radiotherapy regimen of whole breast/chest wall ± regional lymph nodes ±tumor bed: whole breast/chest wall ± regional lymph nodes DT 40.05Gy/15F; Sequential dose increase of DT 2.9 Gy\*3F for tumor bed in breast conserving patients; For patients with a stage of T4 or N3c, it is up to the radiation oncologist to decide whether to proceed with sequential bolsing of locoregional lesions; 4. Patients received adjuvant immunotherapy after neoadjuvant immunotherapy, and the drugs used for postoperative immune maintenance were the immunodrugs used in the neoadjuvant treatment stage; 5. Patients who have not received neoadjuvant immunotherapy and require 1 year of adjuvant immunotherapy and hypofractionated intensity-modulated radiotherapy for whole breast/chest wall ± regional lymph nodes ± tumor beds in the postoperative adjuvant stage. Exclusion Criteria: 1. Failure to complete the course of radiotherapy as planned 2. Concomitant contralateral breast cancer or second primary malignancy (except basal cell carcinoma of the skin and carcinoma in situ of the cervix); 3. Previous history of thoracic radiotherapy; 4. Serious heart, lung, liver, kidney, hematopoietic and nervous system diseases, mental diseases; 5. Concomitant autoimmune diseases such as scleroderma or active lupus erythematosus; pregnant and lactating patients; 6. Patients with prior immunotherapy-related grade 3-4 toxicities during the neoadjuvant immunotherapy phase

Inclusion Criteria: * Male or female Chinese subjects aged 12-65 years * A clinical history of HDM AR/C (Allergic rhinitis/rhinoconjunctivitis) (with or without asthma) and with allergic rhinitis symptoms despite having received allergy pharmacotherapy during the previous year prior to screening * Have a certain level of AR (Allergic rhinitis) symptoms on at least 8 of the last 14 days of the baseline period * Use symptomatic medication for treatment of HDM allergic rhinitis during at least 8 of the last 14 days of the baseline period * Positive skin prick test (SPT) and IgE (Immunoglobulin E) to D. pteronyssinus or D. farinae at screening * Lung function ≥ 70% of predicted value Exclusion Criteria: * Sensitised and regularly exposed to perennial allergens * Any nasal or pharyngeal condition that could interfere with the safety or efficacy evaluation * Asthma requiring treatment with high dose of inhaled corticosteroid * A relevant history of systemic allergic reaction

Inclusion Criteria: 1. Histologically or cytologically confirmed metastatic or advanced-stage solid malignant tumor or HR+/HER2- breast cancer. 2. Have progressed on, were intolerant to, or experienced disease recurrence after standard therapy and have no available effective or tolerable treatment options to derive clinically meaningful benefit. 3. Tumor must have documented specific mutation profile as outlined below based on local laboratory testing. 4. Participants with solid tumors or HR+/HER2- breast cancer with AKT1 E17K mutations. 5. Measurable disease according to RECIST v1.1 criteria. 6. Formalin-fixed paraffin-embedded tumor specimen available for submission. 7. Eastern Cooperative Oncology Group performance status of 0 or 1. Exclusion Criteria: 1. Previously documented activating mutations in KRAS, NRAS, HRAS, or BRAF. 2. Inadequate bone marrow reserve or organ function. 3. Clinically significant abnormalities of glucose metabolism. 4. Participants who are symptomatic or have uncontrolled brain metastases. 5. Requires treatment with certain medications. Participants must meet other inclusion/exclusion criteria.

Inclusion Criteria: * aged 40 or older * receive primary care from participating clinic * diagnosis of type 2 diabetes * most recent hemoglobin A1c (HbA1c) \>7% within the past year * Insomnia Severity Index (ISI) score ≥15 * able to speak English Exclusion Criteria: * diagnosed or self-reported sleep apnea * pregnant or planning to become pregnant during the study period * having a psychiatric or medical condition that would interfere with the ability to complete study procedures * participating in another diabetes clinical trial * living in same household as another participant * required to work night shifts

Inclusion Criteria: 1. Histologically or cytologically confirmed stage II-III (T1cN1-2 or T2-4N0-2) triple-negative breast cancer (TNBC), defined as: * Immunohistochemistry (IHC) showing ER and PR \<1% * HER2-negative per 2028 ASCO-CAP guidelines (IHC 0/1+ or IHC 2+/ISH-) 2. Available tumor tissue sample for biomarker analysis. 3. At least one measurable lesion as per RECIST 1.1 criteria. 4. ECOG performance status 0-1. 5. Adequate organ function as evidenced by: * Absolute neutrophil count ≥1.5×10⁹/L (no G-CSF support within 14 days) * Platelets ≥100×10⁹/L (no transfusion within 14 days) * Hemoglobin \>9 g/dL (no transfusion/ESA within 14 days) * Total bilirubin ≤1.5×ULN * AST/ALT ≤1.5×ULN * Alkaline phosphatase ≤2.5×ULN * Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault) * INR/PT ≤1.5×ULN * TSH within normal range (or normal FT3/FT4 if TSH abnormal) * Normal cardiac enzymes (isolated abnormalities allowed if clinically insignificant) 6. No prior anti-cancer therapy for current diagnosis. 7. For women of childbearing potential and men with WOCBP partners: agreement to use effective contraception from screening until 6 months post-treatment. 8. Willing and able to comply with study procedures and provide written informed consent. Exclusion Criteria: 1. LVEF \<50% by ECHO/MUGA or significant cardiac disease (NYHA Class III/IV). 2. Prior chemotherapy, targeted therapy, or radiotherapy for current breast cancer. 3. Previous treatment with immune checkpoint inhibitors (anti-PD-1/L1, anti-CTLA-4) or T-cell targeting therapies. 4. Prior Trop-2 directed therapy or topoisomerase I inhibitor treatment. 5. Other malignancies within 5 years (except adequately treated CIS of cervix, BCC, or cutaneous SCC). 6. Severe ocular surface disease (dry eye syndrome, meibomian gland dysfunction, or corneal disorders impairing healing). 7. Known hypersensitivity to study drug components. 8. History of immunodeficiency disorders or organ transplantation. 9. Current or history of: * Steroid-requiring interstitial lung disease/pneumoniti Unresolved ILD/pneumonitis on screening imaging Clinically significant pulmonary conditions including: * Recent pulmonary embolism (≤3 months) * Severe asthma/COPD/restrictive lung disease * Pleural effusion requiring intervention * Connective tissue disease with pulmonary involvement * Prior pneumonectomy 10. Active autoimmune disease requiring systemic treatment (past 2 years), except: * Hormone replacement therapy * Physiologic corticosteroid replacement 11. Active infection requiring systemic therapy within 14 days prior to initiation. 12. Uncontrolled comorbidities that may: * Compromise patient safety * Interfere with study completion 13. Any condition that in the investigator's judgment may: * Affect study drug evaluation * Compromise safety assessments * Interfere with data interpretation * Otherwise contraindicate participation

Inclusion Criteria: * Patients with a history of chronic liver disease (CLD) will be included. * Both male and female patients will be included. Exclusion Criteria: * Non-cirrhotic liver patients * Non-cooperative patients.Patients who do not provide written informed consent

Inclusion Criteria: * Histologic documentation of DCIS or invasive breast cancer by core needle or incisional biopsy. * The DCIS or invasive cancer must be estrogen receptor alpha (ER)-positive * The invasive cancer must be HER2-negative (IHC 0-1+, or with a FISH ratio of \<1.8 if IHC is 2+ or if IHC has not been done) * Clinical Stage I-III invasive breast cancer or DCIS * Patients for whom adjuvant treatment with one of the following would be clinically indicated: letrozole, anastrozole, exemestane * Patients who anticipate continuing with adjuvant endocrine therapy for a minimum of 2 years at the time of registration * Women over 18 years of age who are post-menopausal, defined as last menstrual period \>2 years prior to registration, or \>1 year prior to registration with FSH and estradiol in post-menopausal range. * Patients must meet the following clinical laboratory criteria: * Absolute neutrophil count (ANC) \>1,000/mm3 and platelet count \> 75,000/mm3 * Total bilirubin \<1.5 x the upper limit of the normal range (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 x ULN. * Ability to give informed consent. Exclusion Criteria: * Prior endocrine therapy for any histologically-confirmed cancer or prevention of breast cancer in the last 10 years is not allowed. * Any other adjuvant therapy for breast cancer. Exception: Bisphosphonate or denosumab treatment for metabolic bone issues are allowed. * Patients who are prescribed tamoxifen as the first endocrine therapy rather than an aromatase inhibitor. * Women who are pregnant or lactating. * Prisoners.

Inclusion Criteria: * Inclusion Criteria for Educational Institutions * Located in Santiago, Chile. * Secondary education level (grades I-IV Medio). * Coeducational schools. * At least two classes per grade level in secondary education. * A minimum of 30 students per class. * Socioeconomic vulnerability level of ≥ 50%, as measured by the School Vulnerability Index (Índice de Vulnerabilidad Escolar - IVE-SINAE), which includes factors such as parental education and total household income. Inclusion Criteria for Students * Enrolled in grades I, II, or III Medio. * Suicidal ideation within the past month, defined as a score ≥ 3 on the Columbia-Suicide Severity Rating Scale (C-SSRS). * For the Reframe-IT+ program: mild or moderate depressive symptoms, defined as a PHQ-9 score \< 20. * For the CARIBOU program: severe depressive symptoms, defined as a PHQ-9 score ≥ 20. Exclusion Criteria: * Exclusion Criteria for Students * Participation in a structured suicide prevention program (Reframe-IT+) during 2024. * Severe psychotic symptoms, such as perceptual disturbances or delusional ideas, assessed during the eligibility interview. * Suicide attempt(s) in the past three months, assessed during the eligibility interview.

Inclusion Criteria: * Both male and female age range: 18-65 years. * Diagnosed with asthma according to the Global Initiative for Asthma criteria. * Presence of musculoskeletal symptoms; Complaints of chest tightness, neck stiffness, or restricted upper thoracic mobility, often associated with dysfunctional breathing patterns. * Ability to provide informed consent and comply with the treatment protocol. Exclusion Criteria: * clinically unstable or had a neuromuscular disease, unstable cardiovascular disease, or musculoskeletal disease that may interfere with exercise * History of thoracic or cervical spine surgery, trauma, or fractures * Pregnancy or postpartum status * Rheumatologic diseases, a history of musculoskeletal trauma, or musculoskeletal malformations.

Inclusion Criteria: * Female patients aged ≥18 years. * Histologically or cytologically confirmed triple-negative breast cancer (TNBC). * Unresectable locally advanced or metastatic disease. * PD-L1 positive (CPS ≥1 as assessed by central laboratory). * No prior systemic treatment for advanced or metastatic TNBC. * Measurable disease per RECIST v1.1. * ECOG performance status of 0 or 1. * Adequate hematologic, hepatic, and renal function. * Willingness to provide informed consent. Exclusion Criteria: * Prior treatment with any anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies. * Known active central nervous system metastases. * Active autoimmune disease or history of autoimmune disorders requiring systemic treatment. * Active infection requiring systemic therapy. * Pregnancy or lactation. * Other active malignancies requiring treatment within the past 5 years. * History of severe hypersensitivity reactions to study drugs.

Inclusion Criteria 1. Participants will be ≥ 18 years of age. 2. Participants will be females (sex assigned at birth). 3. Participants will be presenting for clinical diagnostic mammography with suspicious calcifications or calcifications associated with other lesion types 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria 1. Females who are breast-feeding will not be eligible for this study 2. Pregnant women will not be included. All females of childbearing potential must attest that they are not pregnant. 3. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. 4. Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.

Inclusion Criteria: * Adolescent is 10-to-14 years old (inclusive) * Adolescent and parent are Latino/a/x/e or Hispanic * Parent and youth have the capacity to provide consent/assent * One parent is willing to participate * Families must be willing to be video or audio recorded for the parent-child interaction task * Youth and parent(s) must be willing to participate as dyads. * Primary language of parent and adolescent is English and/or Spanish Exclusion Criteria: * Parent or adolescent has an intellectual disability, autism spectrum disorder, or other disorder that may limit ability to complete study (surveys and interviews require sustained attention, mental processing, and comprehension). * Adolescent is not 10-to-14 years old * Adolescent and/or parent are not Latino/a/x/e or Hispanic * Primary language of parent and/or adolescent is not English and/or Spanish * Youth and parent(s) are not willing to participate as dyads * Family participated in Phase 1 of the study

Inclusion Criteria: * Participant is a male or female between 18 and 65 years of age, inclusive willing and able and have capacity to provide written informed consent. * Participants must have a primary diagnosis of MDD. Participants with a diagnosis of comorbid generalized anxiety disorder, social anxiety disorder, or panic disorder (with or without agoraphobia) may be included if not the focus of treatment over the past 6 months prior to Screening and the Investigator considers MDD to be the primary diagnosis at Screening and Baseline. * Eligible participants must have a current depressive episode of at least 4 weeks, but no greater than 18 months in duration prior to Screening. * Women of childbearing potential (WOCP) must not plan to become pregnant during the course of the study or be currently breastfeeding. WOCP agree to use an acceptable form of highly effective contraception during participation in the study and for 30 days after receiving the last dose of study treatment. * Body mass index (BMI) between 18 to 40 kg/m2, inclusive. * Participant is willing and able to refrain from the use of drugs of abuse. Exclusion Criteria: * History of, or current presentation consistent with: 1. any depressive episode with psychotic or catatonic features. 2. any bipolar manic, hypomanic or mixed episode, and substance-induced (e.g., antidepressant-induced) manic, hypomanic/mixed episode. 3. bipolar disorder, including history of bipolar depression, or current presentation consistent with bipolar depression. 4. schizophrenia, schizoaffective, or other psychotic disorder. 5. obsessive-compulsive disorder. 6. any persistent neurocognitive disorder. * History of treatment-resistant depression defined as 2 or more failed treatments of adequate dose and duration in the current depressive episode. * Psychiatric hospitalization within current depressive episode. * Evidence or history of clinically significant diseases which can affect the patients' participation. * Previous history of intolerance or significant adverse effects, including drug allergy to allopregnanolone or any components of the SPT-300/placebo formulation. * Participant has a history of drug or alcohol use disorder. * Participants with a positive test for cannabinoids. * Clinically significant risk of suicide or harm to self or others.

Inclusion Criteria: Normotensive participants inclusion criteria: * 18 - 50 years of age, BMI \< 30, blood pressure (BP) within the optimal range according to the latest ESH guidelines (\< 120 mmHg systolic and/or \< 80 mmHg diastolic BP) * Sedentary or low active according to the Global Physical Activity Questionnaire (GPAQ) (Armstrong \& Bull, 2006; Lim et al., 2012) * No prescribed medication and absence of chronic diseases Inclusion criteria for prehypertensive individuals: * 18 - 50 years of age, BMI \< 30 * Diagnosed prehypertension by a clinican from the Hypertension clinic, University clinical centre of Ljubljana using established criteria * Sedentary or low or moderately active according to the Global Physical Activity Questionnaire (GPAQ) * No prescribed medication and absence of chronic diseases Exclusion Criteria: * Blood pressure out of the optimal range (normotensives) * High level of phyisical activity (moderate or high active according to GPAQ) * Hypotension * Chronic diseases * Prescribed medication * Lower extremity injury in the last six months * Menopause * Absence of normal menstrual cycle * Pregnancy * Smoking